Coherus Oncology Target of Unusually Large Options Trading (NASDAQ:CHRS)

Coherus Oncology, Inc. (NASDAQ:CHRS) was the recipient of unusually large options trading on Friday. Stock traders purchased 2,341 call options on the company. This represents an increase of approximately 420% compared to the typical volume of 450 call options.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jefferies Financial Group Inc. increased its stake in Coherus Oncology by 2.5% in the third quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 8,000 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares in the last quarter. Tejara Capital Ltd grew its stake in shares of Coherus Oncology by 1.7% in the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 11,552 shares during the period. BNP Paribas Financial Markets increased its position in Coherus Oncology by 108.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 13,832 shares in the last quarter. Finally, Quarry LP acquired a new position in Coherus Oncology during the 3rd quarter worth approximately $26,000. 72.82% of the stock is owned by institutional investors.

Coherus Oncology Trading Up 27.4%

Coherus Oncology stock traded up $0.44 during trading hours on Friday, reaching $2.03. 9,294,082 shares of the company’s stock were exchanged, compared to its average volume of 1,942,320. The firm’s 50 day simple moving average is $1.38 and its 200 day simple moving average is $1.32. Coherus Oncology has a twelve month low of $0.71 and a twelve month high of $2.17. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $244.76 million, a PE ratio of 1.52 and a beta of 0.96.

Coherus Oncology (NASDAQ:CHRS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $11.57 million for the quarter, compared to the consensus estimate of $13.41 million. Research analysts predict that Coherus Oncology will post -1.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Coherus Oncology in a research note on Wednesday, October 8th. Finally, Oppenheimer assumed coverage on Coherus Oncology in a report on Thursday. They set an “outperform” rating and a $10.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Coherus Oncology presently has a consensus rating of “Hold” and an average target price of $5.51.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.